Alyeska Investment Group’s Genocea Biosciences, Inc. GNCA Stock Holding History

Alyeska Investment Group’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,196,981	Closed	-$3.24M	–	1042
2021 Q1	$3.24M	Buy	+1,196,981	New	+$3.54M	0.04%	395
2020 Q3	–	Sell	-1,196,981	Closed	-$2.75M	–	666
2020 Q2	$2.75M	Sell	1,196,981 -300,519	-20%	-$692K	0.04%	334
2020 Q1	$2.58M	Sell	1,497,500 -2,500	-0.2%	-$5.05K	0.05%	244
2019 Q4	$3.1M	Hold	1,500,000	–	–	0.04%	255
2019 Q3	$4.35M	Hold	1,500,000	–	–	0.06%	239
2019 Q2	$5.88M	Buy	1,500,000 +1,312,500	+700%	+$6.85M	0.08%	215
2019 Q1	$885K	Hold	187,500	–	–	0.01%	323
2018 Q4	$430K	Hold	187,500	–	–	0.01%	335
2018 Q3	$1.17M	Hold	187,500	–	–	0.01%	339
2018 Q2	$1.28M	Hold	187,500	–	–	0.01%	383
2018 Q1	$1.57M	Buy	+187,500	New	+$1.56M	0.01%	367

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Alyeska Investment Group's GNCA Position: Q2 2021 in Review

Alyeska Investment Group sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2021, closing a stake of 128,203 shares — an estimated $347K sold.

Alyeska Investment Group first reported a position in GNCA in Q3 2014 and held it in 21 quarters. The position peaked at $1.93M in Q1 2018. 46 funds tracked by Wall St. Rank hold GNCA as of Q2 2021.

Alyeska Investment Group reported no remaining Genocea Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
Alyeska Investment Group sold 128,203 Genocea Biosciences, Inc. shares in Q2 2021, an estimated $347K.
Alyeska Investment Group first reported a position in Genocea Biosciences, Inc. in Q3 2014 and held it in 21 quarters.
Alyeska Investment Group's Genocea Biosciences, Inc. position peaked at $1.93M in Q1 2018.
46 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2021.

Based on Alyeska Investment Group's 13F filing for Q2 2021, filed 16 Aug 2021.